A Randomized, Double-blind, Placebo Controlled, Sponsor Open, Phase 1b Study To Examine The Adjunctive Safety, Tolerability And Pharmacokinetics Of Pf-02545920 In Psychiatrically Stable Subjects With Schizophrenia
Latest Information Update: 27 Aug 2018
At a glance
- Drugs Mardepodect (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Pfizer
- 11 Oct 2013 Planned End Date changed from 1 Sep 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov record.
- 11 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.